8-K: Crescent Biopharma Secures $185M, Expands Oncology Pipeline

Crescent Biopharma announced a strategic partnership with Kelun-Biotech and a $185 million private placement to accelerate its oncology pipeline, including three programs entering clinical trials in 2026.

Summary

• Crescent Biopharma Operating Company, LLC (Crescent OpCo) entered into two license agreements with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) on December 2, 2025.
• Crescent OpCo granted Kelun-Biotech an exclusive, royalty-bearing license to CR-001 (Crescent's bispecific antibody directed to VEGF and PD-1) in Greater China, receiving an upfront payment of $20.0 million and up to $30.0 million in development milestone payments, plus tiered lowto mid-single digit royalties.
• Kelun-Biotech granted Crescent OpCo an exclusive license to SKB105 (Kelun-Biotech's integrin beta-6-directed antibody-drug conjugate, now CR-003) in all territories outside Greater China. Crescent OpCo will pay $80.0 million upfront, up to $345.0 million in development milestone payments, up to $902.5 million in sales-based milestone payments, and tiered mid-single digits to low-double digit royalties.
• Crescent OpCo also entered into Amendment No. 1 to its License Agreement with Paragon Therapeutics, Inc. relating to CR-001, to accommodate the sublicense with Kelun-Biotech.
• Crescent Biopharma entered into a Securities Purchase Agreement on December 4, 2025, for a private placement of approximately $185.0 million, selling 13,795,685 ordinary shares or pre-funded warrants at $13.41 per share ($13.409 for pre-funded warrants).
• The private placement is expected to close on December 8, 2025, and, combined with existing cash, is believed to fund operations and capital expenditure requirements into 2028.
• Crescent provided pipeline updates, including the planned initiation of global Phase 1/2 clinical trials for CR-001 and CR-003 (SKB105) in Q1 2026, and for CR-002 in H2 2026.
• Proof-of-concept clinical data for CR-001 and CR-003 are anticipated in Q1 2027, and for CR-002 in H2 2027.
• Initial combination data for CR-001 with ADCs, including CR-003, are expected by year-end 2027.

Sentiment

Score: 8

Explanation: The filing details a significant strategic partnership that expands the company's pipeline and accelerates its development strategy, coupled with a substantial private placement that provides a long cash runway. These are strong positive indicators for future growth and stability, despite the associated costs and inherent risks of drug development.

Positives

• The $185.0 million private placement significantly strengthens the balance sheet, providing an anticipated cash runway into 2028.
• The strategic partnership with Kelun-Biotech expands the clinical-stage pipeline with the addition of SKB105 (CR-003), a differentiated integrin beta-6-directed ADC.
• The collaboration accelerates the development of synergistic combination therapies, particularly with CR-001, and enables parallel clinical data generation in global markets and Greater China.
• Three distinct programs (CR-001, CR-002, CR-003) are on track to enter clinical trials in 2026, with multiple data readouts anticipated by year-end 2027.
• CR-001 is a PD-1 x VEGF bispecific antibody designed to replicate the cooperative pharmacology of ivonescimab, which demonstrated superior efficacy results compared to pembrolizumab in a Phase 3 trial.
• CR-002 and CR-003 utilize topoisomerase inhibitor payloads, a class that has shown superior efficacy and safety profiles compared to microtubule inhibitor payloads in cross-trial comparisons.
• Crescent received an upfront payment of $20.0 million from Kelun-Biotech for CR-001 rights in Greater China, providing non-dilutive funding.
• The partnership creates potential for significant future milestone and royalty payments to Crescent from the CR-001 license and to Kelun-Biotech from the SKB105 license, indicating potential for substantial value creation.

Negatives

• Crescent OpCo is required to pay an $80.0 million upfront payment to Kelun-Biotech for the exclusive rights to SKB105, representing a significant cash outflow.
• Crescent is obligated to potential future milestone payments to Kelun-Biotech totaling up to $1.25 billion (development and sales-based), which could be substantial liabilities.
• The private placement of 13,795,685 ordinary shares or pre-funded warrants will result in dilution for existing shareholders.
• Crescent OpCo may be required to pay Kelun-Biotech $5.0 million if Kelun-Biotech initiates a Crescent OpCo approved combination study with CR-001 prior to December 31, 2026.

Risks

• The expected benefits and opportunities related to the strategic partnership with Kelun-Biotech may not be realized by either party or may take longer to realize than anticipated.
• The potential of CR-001 and/or CR-003 may change, and either party may fail to discover and develop commercially successful product candidates through the strategic partnership.
• CR-001, CR-002, or CR-003 may not receive regulatory approval, and if approved, such product candidates may not be commercially successful.
• Crescent has no clinical data regarding cancer patients treated with CR-001, CR-002, or CR-003, and there is no assurance that clinical trials will be completed successfully or produce results necessary to support regulatory approval for commercialization.
• Crescent may not reach the anticipated milestones at the times outlined in the release or at all.
• Crescent has a limited operating history, particularly with respect to clinical trials, and has historical losses with no guarantee of future revenue generation.
• Crescent's ability to raise additional capital to support its business plans is a risk.
• Risks are associated with clinical development and regulatory approval processes.
• Risks related to Crescent's intellectual property exist.
• Crescent relies on third parties to help develop its product candidates, run its clinical trials, and manufacture its product candidates.
• Crescent's dependence on key personnel is a risk factor.
• Crescent's estimates of market opportunity may prove to be inaccurate.
• Significant disruptions of information technology systems or breaches of data security are potential risks.
• Litigation and regulatory risks are inherent in the biopharmaceutical industry.

Future Outlook

Crescent Biopharma anticipates initiating global Phase 1/2 clinical trials for CR-001 and CR-003 (SKB105) in Q1 2026, and for CR-002 in H2 2026. The company expects to report proof-of-concept data for CR-001 and CR-003 in Q1 2027, and for CR-002 in H2 2027. Initial combination data for CR-001 with ADCs, including CR-003, are expected by year-end 2027. The $185 million private placement is projected to provide cash runway into 2028, supporting these key clinical milestones.

Management Comments

• "We are thrilled to be partnering with Kelun-Biotech, an established leader in the development and commercialization of ADCs who shares our commitment to bringing next generation therapeutics that can improve outcomes for people living with cancer." Joshua Brumm, Chief Executive Officer of Crescent.
• "This collaboration expands our pipeline with the addition of SKB105, furthers our strategy of advancing multiple modalities across our portfolio, and accelerates our efforts to deliver synergistic combinations with CR-001, which has the potential to be a foundational backbone therapy." Joshua Brumm, Chief Executive Officer of Crescent.
• "Crescent is now poised to have three distinct programs entering the clinic in 2026 and multiple data readouts anticipated from both monotherapy and novel combination therapy studies by the end of 2027." Joshua Brumm, Chief Executive Officer of Crescent.
• "Additionally, the financing we announced today with leading healthcare investors strengthens our balance sheet, providing anticipated cash runway through multiple key inflection points." Joshua Brumm, Chief Executive Officer of Crescent.
• "Our comprehensive update today underscores Crescents commitment to deliver on our vision of building the next leading biotech oncology company." Joshua Brumm, Chief Executive Officer of Crescent.

Industry Context

The strategic partnership and pipeline expansion position Crescent Biopharma to capitalize on the growing immuno-oncology (I/O) and antibody-drug conjugate (ADC) markets, which are projected to be over $80 billion and $30 billion, respectively. The focus on PD-1 x VEGF bispecific antibodies and topoisomerase inhibitor ADCs aligns with industry trends favoring multi-modal and targeted therapies for solid tumors. The comparison of CR-001 to ivonescimab, which demonstrated superior efficacy to pembrolizumab, highlights the potential for a differentiated product in a highly competitive space dominated by Keytruda.

Comparison to Industry Standards

• CR-001 is designed to replicate the cooperative pharmacology of ivonescimab, which demonstrated superior efficacy results compared to pembrolizumab in a large, third-party Phase 3 trial in non-small cell lung cancer (NSCLC).
• Ivonescimab showed a median progression-free survival (PFS) of 11.14 months compared to 5.82 months for pembrolizumab in the HARMONi-2 study, with a Hazard Ratio (HR) of 0.51.
• Topoisomerase inhibitor payloads (used in CR-002 and CR-003) have consistently demonstrated superior objective response rates (ORR) and lower rates of peripheral neuropathy (a critical adverse event) compared to microtubule inhibitor payloads in cross-trial comparisons, such as Enhertu vs. Kadcyla for HER2 and Dato-DXd vs. PF-06664178 for TROP2.
• CR-003 (SKB105) demonstrated superior cell internalization, anti-tumor response in CDX models, and a superior pharmacokinetic profile (longer half-life, higher ADC exposure) compared to SGN-B6A (Pfizer's ITGB6 MMAE ADC).

Stakeholder Impact

• Shareholders: Potential for long-term value creation through an expanded pipeline and accelerated development, but also short-term dilution from the private placement.
• Employees: Potential for increased research and development activities and growth opportunities due to pipeline expansion and strategic partnerships.
• Customers (future patients): Accelerated development of novel oncology therapeutics, potentially leading to new and improved treatment options for solid tumors.
• Creditors: Improved financial stability and an extended cash runway into 2028 reduce immediate credit risk.
• Partners (Kelun-Biotech, Paragon Therapeutics): Strengthened collaboration and mutual benefits from shared development efforts and expanded market access.

Next Steps

• Closing of the $185.0 million private placement on or about December 8, 2025.
• Initiation of Phase 1/2 trial of CR-001 in Q1 2026.
• Initiation of Phase 1/2 trial of CR-003 (SKB105) in Q1 2026.
• Submission of Investigational New Drug (IND) Application for CR-002 in mid-2026.
• Initiation of Phase 1/2 trial of CR-002 in H2 2026.
• Initiation of the first Phase 1/2 ADC combination trial with CR-001 in H2 2026.
• Reporting of proof-of-concept clinical data from Phase 1/2 trial of CR-001 in Q1 2027.
• Reporting of proof-of-concept clinical data from Phase 1/2 trial of CR-003 (SKB105) in Q1 2027.
• Initiation of Phase 1/2 trial of CR-001 in combination with CR-003 (SKB105) in H1 2027.
• Reporting of proof-of-concept clinical data from Phase 1/2 trial of CR-002 in H2 2027.
• Initial clinical data from first ADC combination Phase 1/2 trial with CR-001 by year-end 2027.
• Initial clinical data from Phase 1/2 trial of CR-001 in combination with CR-003 (SKB105) by year-end 2027.
• Company to continue pursuing pipeline expansion opportunities through internal efforts and with partners, including Kelun-Biotech and Paragon Therapeutics.

Key Dates

Recommendation

The filing outlines a highly positive and transformative period for Crescent Biopharma. The strategic partnership with Kelun-Biotech significantly expands the company's clinical-stage pipeline, adding a promising ADC (CR-003/SKB105) and accelerating the development of synergistic combination therapies, particularly with CR-001, which is designed to replicate a highly successful bispecific antibody. The substantial $185 million private placement, backed by leading healthcare investors, provides a robust cash runway into 2028, de-risking near-term funding concerns and enabling the company to reach multiple key clinical data readouts. The initiation of three distinct clinical programs in 2026 and anticipated proof-of-concept data by year-end 2027 represent significant value-generating catalysts. While drug development carries inherent risks, the strategic alignment, strong financial backing, and promising preclinical data for differentiated assets suggest a strong growth trajectory and significant upside potential for investors.

Keywords

Crescent Biopharma, Kelun-Biotech, strategic partnership, private placement, oncology, bispecific antibody, ADC, CR-001, SKB105, CR-003, PD-1, VEGF, integrin beta-6, solid tumors, clinical trials, biotechnology, pharmaceutical, immuno-oncology, capital raise, Nasdaq